These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35223471)

  • 1. Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.
    Varadarajan I; Ballen K
    Front Oncol; 2022; 12():781479. PubMed ID: 35223471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
    Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
    Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
    Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances and Perspectives in the Treatment of T-PLL.
    Braun T; von Jan J; Wahnschaffe L; Herling M
    Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with white blood cell counts more than a million: A diagnostic and therapeutic challenge.
    Figueroa-Jiménez LA; Cabrera-Márquez AL; Báez-Díaz L; Cáceres-Perkins W
    Bisturi (S Juan); 2016; 2016():12-16. PubMed ID: 29238632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
    Brothers J; Castillo DR; Jeon WJ; Joung B; Linhares Y
    Hematology; 2023 Dec; 28(1):2237342. PubMed ID: 37485976
    [No Abstract]   [Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).
    Guillaume T; Beguin Y; Tabrizi R; Nguyen S; Blaise D; Deconinck E; Redjoul R; Cornillon J; Guillerm G; Contentin N; Sirvent A; Turlure P; Salmon A; Huynh A; François S; Peffault de Latour R; Yakoub-Agha I; Mohty M
    Eur J Haematol; 2015 Mar; 94(3):265-9. PubMed ID: 25130897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
    Murase K; Matsunaga T; Sato T; Kuribayashi K; Kogawa K; Kawano Y; Okamoto T; Takayama T; Watanabe H; Niitsu Y; Hirayama Y
    Int J Clin Oncol; 2003 Dec; 8(6):391-4. PubMed ID: 14663643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
    Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
    George B; Kerridge IH; Gilroy N; Huang G; Hertzberg MS; Bradstock KF; Gottlieb DJ
    Transpl Infect Dis; 2012 Apr; 14(2):141-8. PubMed ID: 22283838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
    Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
    Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
    Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat prolymphocytic leukemia.
    Dearden C
    Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
    Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
    Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
    Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.